Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Vernalis LSE:VER London Ordinary Share GB00B3Y5L754 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 6.17p 0.00p 0.00p - - - 0 05:00:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 12.0 -15.3 -3.2 - 32.48

Vernalis Share Discussion Threads

Showing 3176 to 3197 of 3850 messages
Chat Pages: Latest  130  129  128  127  126  125  124  123  122  121  120  119  Older
DateSubjectAuthorDiscuss
20/5/2016
07:57
Nice little set up in Clonmel. Two units, one dedicated to beta lac tam antibiotics and the other set up and registered for a range of products including restricted items- presumably opiates.I'm sure there will be interested folk out there,but whether it has enough capacity to be viable?
fhmktg
20/5/2016
06:54
It seems like the business will be kept going for now, so its certainly not an immediate fire sale liquidation (see link) http://www.irishtimes.com/business/health-pharma/more-than-130-jobs-at-risk-at-tipperary-s-suir-pharma-1.2650705 However, I'm surprised that Vernalis went with just one supplier in the NDA, it is normal industry practice to register at least two suppliers for the AS, this implies a lack of forward thinking and/or poor risk assessment from the Vernalis management.
timbo003
20/5/2016
06:33
If the business is sold as a going concern then no problem. The administrators will be keen to keep ongoing customers either by continuing to supply product while a buyer is sought or factoring in future business from VRN in the sale value. Suggest this is a market over-reaction.
zipstuck
19/5/2016
15:31
was this manipulated down so that the buyer of 500000 could buy these at a discount?
twodegrees
19/5/2016
15:19
if the company was informed yesterday why are they just realising the bloomin news at 16.11pm....totally out of order.
twodegrees
01/5/2016
10:18
Have a look at the cost of a bottle of the cough treatment.some insurance companies refuse to pay and some patients refuse to buy it when they see their copay contribution.it is sustained release codeine / chlorpheniramine mixture .to buy as syrup and tabs in the UK would cost about £6 but you would have to take them 4 times a day.the advantage of their product is its twice daily dosage. Codeine in the states is governed by tough laws and is not available without a prescription
haroldthegreat
28/4/2016
13:27
Read Edison's note on VERNALIS, out this morning, by visiting hxxps://www.research-tree.com/company/GB00B3Y5L754 "Vernalis intends to raise £40m (gross) through the issue of 80m new shares at 50p per share. This equity raise will remove any uncertainty over whether Vernalis’s cash position is sufficient to take it through to sustainable profitability in FY18 (on our current forecasts). New funds will be used to boost existing working capital required for a conservative Tuzistra XR roll-out, upcoming Moxatag re-launch and future launches of the remaining four US cough cold programmes in development with Tris. The share placing is on a non pre-emptive basis and is conditional on being passed at the General Meeting scheduled on 12 May 2016 ..."
thomasthetank1
26/4/2016
16:26
Cos we are a pain in the ar*e
ffp
26/4/2016
13:36
p.s why are the current shareholders not allowed to buy any at a discounted price.
twodegrees
26/4/2016
13:35
If they already have so much cash in hand, why the need for another placing. Is it that they can get money at cheap interest rates and they are thinking for the future.
twodegrees
14/4/2016
09:32
Steady progress on the new formulations- winter season 2017/8 for the launches to be complete? It will be interesting what else they snap up to keep the sales team busy for the next three years. Looks like fy 2020 before we see real pattern of income established? Enough cash to see us through though. Any comments or more optimistic views?
fhmktg
06/4/2016
14:10
Check out who pays Edison to write that
buywell3
06/4/2016
14:08
Read Edison’s note on Vernalis (VER), out this morning, by visiting www.research-tree.com … “Vernalis reported a modest £0.6m in Tuzistra XR sales over the first four months post-launch due to the mild cough cold season. The US launch of this prescription-only (Rx), extended release (ER) cough cold medicine is the first step in Vernalis’s transition into a commercial-stage speciality pharma company, targeting a $3.5bn market opportunity. The emphasis for year one of Tuzistra XR commercialisation is...”
thomasthetank1
23/3/2016
16:30
Some sizeable trades!
fhmktg
20/3/2016
16:13
I'm new to this company however on the face of it doesn't look cheap despite recent falls, market cap of well over 200 million and tiny revenues, obviously the healthy cash position accounts for part of the value however the remaineder is valued at around 175 million, seems steep to me. Realistically is there much chance of revenues increasing substantially over the next 12 - 24 months ??
eastbourne1982
18/3/2016
16:01
Bought for 'clients of Woodford ' I wonder who he is talking to and working with?
fhmktg
18/3/2016
14:34
mr woodford 25%+ and still it falls...
twodegrees
17/3/2016
17:12
lol !!!! lol !!!!!! Seems like the charts run the business.
hvs
17/3/2016
16:49
free stock charts from uk.advfn.com
buywell2
17/3/2016
15:51
No worries two degrees. Hang in there
hvs
17/3/2016
15:49
large buys or roll overs...in any case good size amounts
twodegrees
17/3/2016
15:15
54 million in cash and no debt as at 31st dec....I bet a lot of companies would like that...don't forget a lot of front end costs to get products to market so in time the profits will come.
twodegrees
Chat Pages: Latest  130  129  128  127  126  125  124  123  122  121  120  119  Older
Your Recent History
LSE
VER
Vernalis
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181211 05:16:39